{"id":74608,"date":"2026-05-30T10:16:47","date_gmt":"2026-05-30T10:16:47","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/74608\/"},"modified":"2026-05-30T10:16:47","modified_gmt":"2026-05-30T10:16:47","slug":"roche-shares-fall-after-breast-cancer-treatment-misses-goal-in-late-stage-study-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/74608\/","title":{"rendered":"Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study"},"content":{"rendered":"<p data-type=\"paragraph\" data=\"[object Object]\" class=\"css-1qg6i2u eku5yup0\">Roche Holding shares fell after the company said a late-stage study for an experimental breast-<a data-type=\"subject\" href=\"https:\/\/www.wsj.com\/topics\/subject\/cancer\" target=\"_blank\" class=\"ekxajjj0 css-i0lbhy-OverridedLink\" rel=\"nofollow noopener\">cancer<\/a> treatment missed its primary objective.<\/p>\n<p data-type=\"paragraph\" data=\"[object Object]\" class=\"css-1qg6i2u eku5yup0\">The results of the clinical trial mark a setback for the Swiss pharmaceutical company, which saw in the drug, giredestrant, a candidate to become a blockbuster treatment. The drugmaker, though, said there was still a path forward for the medicine.<\/p>\n<p class=\"css-16aepit e1jdulti0\">Copyright \u00a92026 Dow Jones &amp; Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8<\/p>\n","protected":false},"excerpt":{"rendered":"Roche Holding shares fell after the company said a late-stage study for an experimental breast-cancer treatment missed its&hellip;\n","protected":false},"author":2,"featured_media":74609,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[207,6276,6277,2112,25359,39269,14605,39267,6274,1126,6273,39265,2115,6286,38020,197,6275,39272,834,16097,2783,1002,4128,25348,6288,1831,39271,228,25357,37715,39266,25362,25354,25361,25349,6263,206,25358,23809,8332,337,10728,25356,12436,1138,25351,338,25350,134,994,39268,25363,12081,6285,6268,39270,17,6278,6267,16009,6279],"class_list":["post-74608","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-breast-cancer","tag-ce-exclusion-filter","tag-ce-industry-news-filter","tag-cancer","tag-chnovn","tag-chrog","tag-commodity","tag-commodity-financial-market-news","tag-content-types","tag-corporate","tag-corporate-industrial-news","tag-demographic-health","tag-development","tag-disruptions","tag-equity-markets","tag-europe","tag-factiva-filters","tag-financial-market-news","tag-financial-performance","tag-gcapi","tag-general-news","tag-health","tag-healthcare","tag-healthcare-life-sciences","tag-industrial-news","tag-life-sciences","tag-linkendrnrealtime-linkedarticle-dnco20260309006286","tag-manufacturing","tag-medical-conditions","tag-medical-treatments","tag-medical-treatments-procedures","tag-new-product","tag-new-product-service-testing","tag-new-products","tag-new-products-services","tag-newsplus","tag-novartis","tag-novn-eb","tag-pfe","tag-pfizer","tag-pharmaceuticals","tag-political","tag-political-general-news","tag-procedures","tag-products","tag-products-services","tag-research","tag-research-development","tag-roche","tag-roche-holding","tag-rog-eb","tag-service-testing","tag-services","tag-share-price-movement","tag-share-price-movement-disruptions","tag-stefan-frings","tag-switzerland","tag-synd","tag-western-europe","tag-womens-health","tag-wsj-pro-wsj-com"],"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/74608","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=74608"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/74608\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/74609"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=74608"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=74608"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=74608"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}